Faculty Of IDS 2019

Here are some of the International Speakers

Dr. Ananda Basu, USA

Dr. Ananda Basu is the Harrison Professor in the Division of Endocrinology at the University of Virginia. He is the past Chair of the Hospital Diabetes Practice at Mayo Clinic. Dr. Basu is currently the Principal Investigator of two NIH funded projects- NIDDK-DP3-106785 that attempts to recreate a truly electronic beta cell by infusing insulin and amylin and NIDDK-R01-085516 that seeks to understand the altered physiology of the alpha cell in humans with and without type 1 diabetes. He is also a consultant in a project that seeks to introduce the first indigenous artificial pancreas for patients with type 1 diabetes. Dr. Basu is the author of almost 200 peer-reviewed publications in major journals including the New England Journal of Medicine, Journal of Clinical Investigation and Diabetes. He has been on the editorial board of Diabetes Care and currently is an Associate editor of the Diabetes Technology and Therapeutics journal.

Dr. C.B Sanjeevi, Sweden

Dr. Carani B Sanjeevi MD, PhD is a Professor at the Karolinska Institute (KI) in the Department of Medicine. He heads a research group "Diabetes Immunology" at the Center for Molecular Medicine in Karolinska University Hospital, Solna campus in Stockholm. Dr. Sanjeevi is also Senior Advisor to the Innovation office of Karolinska Institute. He is considered to be a global authority in diabetes, particularly autoimmune diabetes.

Prof. Leif Groop, Sweden

Prof. Leif Groop is a Professor in Endocrinology at Lund University and Director of Lund University Diabetes Centre. He is also Academy of Finland Finnish Distinguished Professor (FiDiPro) at the Institute for Molecular Medicine Finland (FIMM). After a PostDoc period at Yale University he devoted his research to dissection of the heterogeneity of diabetes and to explore the pathogenic events leading to type 2 diabetes. He initiated the Botnia Study in Finland, one of the world's largest family studies on type 2 diabetes. The research group has been involved in many of the genetic discoveries on type 2 diabetes during the past 15 years, including one of the first whole genome association studies for type 2 diabetes. His ground breaking paper on the different subtypes of diabetes this year waves worldwide.

Dr. Pankaj Shah, USA

Dr.Pankaj Shah is an Endocrinologist, at the Mayo Clinic, Rochester, MN, USA.Dr Shah trained and worked at the AIIMS, Delhi, prior to moving to Mayo Clinic, US in 1997. He has a rich international experience in endocrinology, having also worked at the Creighton University, MD Anderson Center and at University of Texas. Dr Shah is on the editorial board of Endocrine Practice. He is internationally renowned and has an interest in management of diabetes in patients with complex clinical conditions and also in hypoglycemia management.

Dr. Rita Basu, USA

Dr. Rita Basu is a Professor in the Division of Endocrinology at the University of Virginia. She is working on Translational Research for diabetes at UVA School of Medicine and Center for Diabetes Technology. She is currently the Principal Investigator on several NIH grants. She has had a long and productive career as an expert in the Ethics of Research and Human subject protection having served on the Institutional Review Board as the Associate Medical Director for 3 years and also a Chair of the IRB for over a decade at Mayo Clinic. She has authored more than 150 peer-review publications in diabetes. She has expertise in integrative physiology and translational research, ethical conduct of research, federal regulations guiding research and diabetes training and education.

Dr. Suresh Chari, USA

Dr. Suresh Chari is currently Professor of Medicine at Mayo College of Medicine, Rochester, M.N. He has been the Director of Pancreas Clinic at Mayo Clinic, Rochester and past President of the American Pancreatic Association. He has been a Councellor of the International Association of Pancreatology(IAP) and is the President Elect of the IAP. He has over 250 (277) publications in the field of pancreatology. His research spans the breadth of pancreatic diseases including tropical chronic pancreatitis and pancreatic cancer. He has had NIH funding since 2003 for study of new- onset Diabetes as an early marker of pancreatic cancer. His current project, "Pancreatic Cancer-induced Diabetes: A Clue to its Early Diagnosis" has the long-term programmatic goals to facilitate early detection of pancreatic cancer. He is also interested in the effects of type 1 and type 2 Diabetes on the exocrine pancreas, a condition that he has termed " Diabetic exocrine pancreatopathy".

Professor Susan Wong, UK

Prof. Susan Wong is a Professor of Diabetes and Metabolism, at Cardiff University, UK. She has many years of research experience in working on the aetiology and pathogenesis of type 1 diabetes. Prof. Wong has also included the role of the gut microbiome. As a member of the Type 1 Diabetes Consortium, she has also been involved in translational work in developing immunotherapy for type 1 diabetes and in early phase 1a clinical trials.

Dr. Vinaya Simha, USA

Dr. Vinaya Simha, MBBS, MD is a Consultant in the Division of Endocrinology, and Assistant Professor, Department of Internal Medicine at Mayo Clinic, Rochester, MN. He is board certified in Internal Medicine, Endocrinology and Clinical Lipidology. His research interests include lipodystrophy and the role of body fat distribution on glucose and lipid homeostasis, and has many publications in the field of lipodystrophy and leptin-replacement therapy. He has a keen interest in clinical lipidology and is an investigator in some of the early trials of PCSK9 inhibitors.

Faculty Of IDS 2018

Dr. Ananda Basu, USA

Dr. Ananda Basu is a Professor of Medicine in the Division of Endocrinology, Mayo Clinic Rochester, USA. He is the past Chair of the Hospital Diabetes Practice at Mayo Clinic. His clinical accomplishments include standardizing and protocolizing care of all inpatients at Mayo Clinic Hospitals. His research work relates to the development of individualized, physiology-informed artificial pancreas closed loop systems for management of Type 1 diabetes and in integrated physiology of carbohydrate metabolism in humans. He has authored more than 175 original articles, book chapters and reviews on pathophysiology of diabetes. Dr. Basu is a principal investigator on several NIH grants. He is a "Clinician-Investigator" at Mayo Clinic and appointed as one of the 50 best doctors ever employed at the Mayo Clinic.

Dr. Andrew JM Boulton, UK

Dr. Boulton is a Professor of Medicine at Manchester University. He has authored more than 500 peer-reviewed manuscripts and book chapters, mainly on diabetic lower limb and renal complications. Among his many awards, he has received the ADA's Roger Pecoraro Lectureship, the EASD Camillo Golgi prize and was the first recipient of the international award on diabetic foot research. He was the 2008 winner of the ADA's Harold Rifkin award for distinguished international service in diabetes. He is a previous editor of Diabetic Medicine and is currently an associate editor of Diabetes Care. He was the founding Chairman of the Diabetic Foot Study Group. Until recently he was President of the EASD.

Dr. C.B Sanjeevi, Sweden

Dr. Carani B Sanjeevi MD, PhD is a Professor at the Karolinska Institute (KI) in the Department of Medicine. He heads a research group "Diabetes Immunology" at the Center for Molecular Medicine in Karolinska University Hospital, Solna campus in Stockholm. Dr. Sanjeevi is also Senior Advisor to the Innovation office of Karolinska Institute. Dr. Sanjeevi serves in the Board of Cadila Pharma Sweden AB, Oncology Ventures, Denmark and serves as member of the Scientific Advisory Board of Seraxis, USA and Diamyd Medical AB, Sweden. He is advisor to HBM Bioventures, Switzerland and TATA Capital Healthcare Private Equity Fund, Mumbai.

Dr. David Leslie, UK

Dr. David Leslie is Professor of Diabetes and Autoimmunity at St Bartholomew's Hospital and University of London. He was recently elected President of The Association of Physicians of Great Britian and Ireland. He has an interest in the cause of autoimmune diabetes through the study of twins and disease syndromes. David Leslie is the Reviews Editor of Diabetic Medicine and was on the Editorial Board of several major Journals. He is Director of the European Consortium Action LADA, Director of the British Diabetic Twin Trust, a member of the NIH Advisory Board on the Prevention of Diabetes, and is a Trustee of the British Twin Trust and the Muirhead Trust. He is an internationally renowned authority in the field of diabetes and autoimmunity.

Dr. Desmond Schatz, USA

President of ADA and professor in University of Florida, Dr Schatz is Professor and Associate Chairman of Pediatrics, Medical Director of the Diabetes Center and Associate Director of the GCRC at the University of Florida, Gainesville. He has been involved in Type 1 Diabetes research since the mid-80s and has published over 200 manuscripts, the majority related to the prediction, natural history, genetics, immunopathogenesis and prevention of the disease, as well as the management of children and adolescents with Type 1 Diabetes. He is the Principal Investigator (PI) on several JDRF and NIH awards. He serve as the president for the American Diabetes Association in 2016.

Dr Eva Ortqvist, Sweden

Dr Eva Ortqvist is an internationally renowned Paediatric Endocrinologist, who is a consultant at the Karolinska institute in Stockholm. She has extensive experience and publication in the field of childhood and adolescent diabetes. She is recognised as an international expert in the use of insulin pump therapy and in the autoimmune markers of Type 1 diabetes as well as autoimmune thyroid disease.

Dr. Massimo Porta, Italy

Massimo Porta a Professor at The Turin University was granted his PhD at the Royal Postgraduate Medical School, London University, UK in 1983, where he worked on diabetic eye disease. Currently, he is Head of the Unit of Internal Medicine and of the Diabetic Retinopathy Centre. Professor Porta is Past-President of the Study Group on Eye Complications of Diabetes of the European Association for the Study of Diabetes (EASDec), and Convenor of the Working Group of the Saint-Vincent Declaration for the prevention of Diabetes-Related Blindness in Europe, supported by the World Health Organization and the International Diabetes Federation (1985-95) and Honorary Secretary of the European Association for the Study of Diabetes (EASD) in 1999-2001. Professor Porta's research interests include the pathogenesis of diabetic retinopathy, prevention of diabetes-related blindness and Group Care, a new model to manage chronic diseases. Professor Porta has authored 168 papers in indexed journals, 101 other articles, 44 chapters, and edited or co-edited 13 books/monographs. He is Editor-in-Chief of Acta Diabetologica (IF 2015 3.079

Dr Michael Alvarsson , Sweden

Dr Michael Alvarsson is a professor at Karolinska University, working at the Clinic of Endocrinology, Metabolism and Diabetes. He also conducts clinical diabetes research at the Department of Molecular medicine and Surgery (MMK) at Karolinska Institute. He is widely known for his clinical studies on B-cell rest and the hypothalamo-pituitary- adrenal axis on metabolic control in diabetics and clinical studies on the effects of training on patients with type 2-diabetes. Some of his recent publications include- effect of high dose of Vitamin D on beta cell function (an RCT), gender differences in type 2 diabetes course/ outcomes, and ACTH sensitivity in diabetes.

Dr. Peter Adolfsson, Sweden

Dr. Peter Adolfsson, an internationally well known expert on advances in diabetes therapy, is a Faculty at the Institution for Clinical Sciences, Sahlgrenska Academy, at University of Gothenburg, Sweden. His research has centered around the use of technology in type 1 diabetes, and he is renowned for his work on the same. He has co-authored the exercise guideline-related consensus statement of the International Society of Pediatric and Adolescent Diabetes. An expert on insulin pumps and continuous glucose monitoring, the he is also working on projects that attempt to solve the special needs of chidren with type 1 diabetes. His work has been well cited, and has been published in journals such as Pediatric Diabetes, Diabetes Technology and Therapuetics and Diabetes Medicine.

Dr. Rita Basu, USA

Dr. Rita Basu is a Professor of Medicine in the Division of Endocrinology, Mayo Clinic Rochester, USA. She is Chair of the Institutional Review Board for the Mayo Clinic. She is Co-Director of international educational programs set up under WHO. Her research spans two decades and focuses on clinical and translational medicine related to Diabetes. Her current work relates to overnight glucose control in type 2 diabetes, clinical trials in NAFLD/NASH, novel glucose sensing and the development of an artificial pancreas. Dr. Basu is principal investigator on multiple NIH, Foundation and Industry grants. She has authored more than 120 original articles, books, and chapters on diabetes.

Dr. Vinaya Simha, USA

Dr. Vinaya Simha, MBBS, MD is a Consultant in the Division of Endocrinology, and Assistant Professor, Department of Internal Medicine at Mayo Clinic, Rochester, MN. He is board certified in Internal Medicine, Endocrinology and Clinical Lipidology. His research interests include lipodystrophy and the role of body fat distribution on glucose and lipid homeostasis, and has many publications in the field of lipodystrophy and leptin-replacement therapy. He has a keen interest in clinical lipidology and is an investigator in some of the early trials of PCSK9 inhibitors.

Dr. Ake Ortqvist, Sweden

Dr Ake Ortqvist is a faculty at Karolinska Institute. He is the former Head of Department of Infectious Disease at Karolinska University Hospital. He also headed the Department of Communicable Disease Control in Stockholm County, Sweden. He is an authority in influenza and pneumococcal vaccinations. Dr Ake has special expertise on vaccination strategies in high risk subjects such as people with diabetes. He will be talking on prevention of influenza in people with diabetes and the clinical strategies for vaccination in diabetes.




International Speakers of IDS 2017

Dr. Ananda Basu, USA

Dr. Ananda Basu is a Professor of Medicine in the Division of Endocrinology, Mayo Clinic Rochester, USA. He is the past Chair of the Hospital Diabetes Practice at Mayo Clinic. His clinical accomplishments include standardizing and protocolizing care of all inpatients at Mayo Clinic Hospitals. His research work relates to the development of individualized, physiology-informed artificial pancreas closed loop systems for management of Type 1 diabetes and in integrated physiology of carbohydrate metabolism in humans. He has authored more than 175 original articles, book chapters and reviews on pathophysiology of diabetes. Dr. Basu is a principal investigator on several NIH grants. He is a "Clinician-Investigator" at Mayo Clinic and appointed as one of the 50 best doctors ever employed at the Mayo Clinic.

Dr. Annika Janson, Sweden

Dr. Annika Janson is the former Head of the Section for Diabetes, Endocrinology, Metabolic Disease and Obesity (DEMO) at the Karolinska University Hospital, the largest pediatrics endocrinology center among the Nordic countries. Her research focuses on clinical studies in ketoacidosis, insulin pumps therapy and bariatric surgery in adolescents.

Dr. C.B Sanjeevi, Sweden

Dr. Carani B Sanjeevi MD, PhD is a Professor at the Karolinska Institute (KI) in the Department of Medicine. He heads a research group "Diabetes Immunology" at the Center for Molecular Medicine in Karolinska University Hospital, Solna campus in Stockholm. Dr. Sanjeevi is also Senior Advisor to the Innovation office of Karolinska Institute. Dr. Sanjeevi serves in the Board of Cadila Pharma Sweden AB, Oncology Ventures, Denmark and serves as member of the Scientific Advisory Board of Seraxis, USA and Diamyd Medical AB, Sweden. He is advisor to HBM Bioventures, Switzerland and TATA Capital Healthcare Private Equity Fund, Mumbai.

Dr. Lars Ryden, Sweden

Dr. Lars Ryden is Senior Professor of Cardiology at the Karolinska Institute, Stockholm, Sweden. He specializes in internal medicine and cardiology, with a focus on heart failure and cardiovascular disease related to diabetes. Professor Ryden has published more than 700 scientific papers. He is an honorary member of the Royal College of Physicians, London, UK, and several national cardiac societies. Prof Ryden chaired the Task Forces that prepared the 2007 and 2013 ESC/EASD Guidelines for Diabetes, Prediabetes and Cardiovascular Disease.

Dr. Linda Mellbin, Sweden

Dr. Linda Mellbin from the Karolinska University, Dr Mellbin currently works as senior cardiologist at the Coronary Care Unit since 2009. She obtained her PhD in 2010 with her studies on glucose-control therapies and biomarkers in myocardial infarction and Diabetes. Dr. Mellbin has continued her research in the field of biomarkers, in particular related to hormonal systems. She participates in several clinical trials on Diabetes and cardiovascular disease.

Dr. Peter Adolfsson, Sweden

Dr. Peter Adolfsson, an internationally well known expert on advances in diabetes therapy, is a Faculty at the Institution for Clinical Sciences, Sahlgrenska Academy, at University of Gothenburg, Sweden. His research has centered around the use of technology in type 1 diabetes, and he is renowned for his work on the same. He has co-authored the exercise guideline-related consensus statement of the International Society of Pediatric and Adolescent Diabetes. An expert on insulin pumps and continuous glucose monitoring, the he is also working on projects that attempt to solve the special needs of chidren with type 1 diabetes. His work has been well cited, and has been published in journals such as Pediatric Diabetes, Diabetes Technology and Therapuetics and Diabetes Medicine.

Dr. Rita Basu, USA

Dr. Rita Basu is a Professor of Medicine in the Division of Endocrinology, Mayo Clinic Rochester, USA. She is Chair of the Institutional Review Board for the Mayo Clinic. She is Co-Director of international educational programs set up under WHO. Her research spans two decades and focuses on clinical and translational medicine related to Diabetes. Her current work relates to overnight glucose control in type 2 diabetes, clinical trials in NAFLD/NASH, novel glucose sensing and the development of an artificial pancreas. Dr. Basu is principal investigator on multiple NIH, Foundation and Industry grants. She has authored more than 120 original articles, books, and chapters on diabetes.

Dr. Roger Mazze, USA

Dr. Roger Mazze received his PhD from the University of Illinois following a fellowship at Brandeis University's Lemberg Center. He joined the Albert Einstein College of Medicine faculty in 1974, and was promoted in 1987 to Professor. He was executive director of the Diabetes Research and Training Center and the first WHO Collaborating Center. In 1988 he became professor and senior vice president of the International Diabetes Center where he is credited with the development of the ambulatory glucose profile (AGP) as the first standardized report from SMBG and CGM. He also developed and directed the first WHO-recognized technology laboratory (under the auspices of the WHO Collaborating Center at the IDC and Mayo Clinic) Dr. Mazze was also a founder of the affiliated diabetes centre program at Nanjing Medical University where he is appointed visiting professor.

Dr. Sam Dagogo-Jack, USA

Dr. Sam Dagogo-Jack, is Professor in the Division of Endocrinology, Diabetes & Metabolism and Director, General Clinical Research Center at the University of Tennessee, USA. A former President of the American Diabetes Association, he is considered one of the world's leading thought leaders in diabetes. His research has centered around the mechanistic basis of diabetes and Prediabetes. His work has been published widely, in journals such as the Journal of Clinical Endocrinology and Metabolism and Hormone Research. He developed the first radioimmunoassay for epidermal growth factor (EGF) in human saliva, and also- his work with Dr. Philip E. Cryer, led to the discovery of the syndrome of hypoglycemia-associated autonomic failure, paving way to approaches to the management of the same. In addition to cutting edge research work, Dr Sam Dagogo-Jack's commitment to community work, and diabetes awareness programs has been widely acclaimed.

Dr. Suresh Chari, USA

Dr. Chari is currently Professor of Medicine at Mayo Clinic College of Medicine, Rochester, MN.He has been the Director of Pancreas Clinic at Mayo Clinic Rochester and past President of the American Pancreatic Association. He has been a Councilor of the International Association of Pancreatology (IAP) and is the President-Elect of the IAP. He has over 250 publications in the field of pancreatology. His research spans the breadth of pancreatic diseases including tropical chronic pancreatitis and pancreatic cancer. He has had NIH funding since 2003 for study of new-onset Diabetes as an early marker of pancreatic cancer. He is currently conducting a clinical trial of screening for pancreatic cancer in subjects with new-onset Diabetes. He is also interested in the effects of type 1 and type 2 Diabetes on the exocrine pancreas, a condition that he has termed "Diabetic exocrine pancreatopathy".

Dr. Vinaya Simha, USA

Dr. Vinaya Simha, MBBS, MD is a Consultant in the Division of Endocrinology, and Assistant Professor, Department of Internal Medicine at Mayo Clinic, Rochester, MN. He is board certified in Internal Medicine, Endocrinology and Clinical Lipidology. His research interests include lipodystrophy and the role of body fat distribution on glucose and lipid homeostasis, and has many publications in the field of lipodystrophy and leptin-replacement therapy. He has a keen interest in clinical lipidology and is an investigator in some of the early trials of PCSK9 inhibitors.

Dr. William Rust, USA

Dr. William Rust is the Head, Seraxis, and former Director of Cell Biology at the American Type Culture Collection, USA.
Dr. William Rust is among the eminent stem cell researchers in the world. Founder of Seraxis, his work has focused on clinical aspects of stem cell therapy in diabetes. He is a leader in embryonic stem cell therapeutics, and in induced pluripotent stem cell- based treatments. Dr Rust has worked in US and Singapore to develop cell therapies for diabetes and cardiovascular disease. He holds patents, has published in reputed journal, and has been awarded the President's Graduate Fellowship. He is currently working towards clinical studies on a practical cell-based therapy for insulin dependent diabetes.